ArticleDrug safety2013
Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.
Article in Drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies.American journal of epidemiology · 2024Review
- Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.Drug safety · 2023Article
- Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances.Frontiers in pharmacology · 2021Article
- How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.Harvard data science review · 2020Article
- From Data Silos to Standardized, Linked, and FAIR Data for Pharmacovigilance: Current Advances and Challenges with Observational Healthcare Data.Drug safety · 2019Article
- Scientific Opinion of the PPR Panel on the follow-up of the findings of the External Scientific Report 'Literature review of epidemiological studies linking exposure to pesticides and health effects'.EFSA journal. European Food Safety Authority · 2017Article
- IT-CARES: an interactive tool for case-crossover analyses of electronic medical records for patient safety.Journal of the American Medical Informatics Association : JAMIA · 2017Article
- Article
- Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies.EGEMS (Washington, DC) · 2016Article
- Desiderata for computable representations of electronic health records-driven phenotype algorithms.Journal of the American Medical Informatics Association : JAMIA · 2015Article
- A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.Drug safety · 2015Observational
- Review
- Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks.Drug safety · 2015Article
- Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology".Drug safety · 2015Article
- Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network.Drug safety · 2014Article
- Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.Drug safety · 2013Article
- Desideratum for evidence based epidemiology.Drug safety · 2013Review
- The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.Drug safety · 2013Article
- Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.Drug safety · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA systematic risk identification system has the potential to test marketed drugs for important Health Outcomes of Interest or HOI. For each HOI, multiple definitions are used in the literature, and some of them are validated for certain databases. However, little is known about the effect of different definitions on the ability of methods to estimate their association with medical products.
objectivesAlternative definitions of HOI were studied for their effect on the performance of analytical methods in observational outcome studies.
methodsA set of alternative definitions for three HOI were defined based on literature review and clinical diagnosis guidelines: acute kidney injury, acute liver injury and acute myocardial infarction. The definitions varied by the choice of diagnostic codes and the inclusion of procedure codes and lab values. They were then used to empirically study an array of analytical methods with various analytical choices in four observational healthcare databases. The methods were executed against predefined drug-HOI pairs to generate an effect estimate and standard error for each pair. These test cases included positive controls (active ingredients with evidence to suspect a positive association with the outcome) and negative controls (active ingredients with no evidence to expect an effect on the outcome). Three different performance metrics where used: (i) Area Under the Receiver Operator Characteristics (ROC) curve (AUC) as a measure of a method's ability to distinguish between positive and negative test cases, (ii) Measure of bias by estimation of distribution of observed effect estimates for the negative test pairs where the true effect can be assumed to be one (no relative risk), and (iii) Minimal Detectable Relative Risk (MDRR) as a measure of whether there is sufficient power to generate effect estimates.
resultsIn the three outcomes studied, different definitions of outcomes show comparable ability to differentiate true from false control cases (AUC) and a similar bias estimation. However, broader definitions generating larger outcome cohorts allowed more drugs to be studied with sufficient statistical power.
conclusionsBroader definitions are preferred since they allow studying drugs with lower prevalence than the more precise or narrow definitions while showing comparable performance characteristics in differentiation of signal vs. no signal as well as effect size estimation.
Indexed as
Identifiers
24166234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.